Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Measurements Fail To Identify TB Patients Who Could Benefit From Shorter Treatment Course
Tuberculosis (TB) is a difficult infection to treat and requires six months of multiple antibiotics to cure it. To combat the TB pandemic, a shorter and simpler drug treatment would be a huge advance since most TB occurs in re-limited settings with poor public health infrastructures. Don't forget to buy zoloft online no prescription.

Investigation Urgently Needed Into Treatment Of Mentally Ill Immigration Detainees At California Facility, Editorial States
"Although the number of mentally ill immigration detainees" at the La Mesa, Calif.-based private psychiatric hospital Alvarado Parkway Institute "at any one time seems to range from as few as two to only five or so, their situation needs to be addressed quickly," a San Diego Tribune editorial states (San Diego Tribune, 5/19). Some disability rights lawyers and advocates for the mentally ill say that conditions at many of the private facilities, including API, violate state and federal laws governing treatment of mentally ill people. Ann Menasche, a lawyer with the legal advocacy group Disability Rights California, last month sent a letter to the U.S. Immigration and Customs Enforcement claiming that after visiting API and interviewing detainees, she found that the conditions are "excessive, unjustifiable and punitive" (Kaiser Health Disparities Report, 5/18).According to the Tribune, "California"s strict patients" rights laws specify that psychiatric patients can have daily visitors, use the telephone, exercise, socialize and be free from restraint unless the chief of the facility determines that a specific individual is a threat to himself or others," but, according to Menasche, patients at API are being denied those rights. The editorial adds that the conditions Menasche describes "may sound appalling, but it is unclear whether they are proper for the circumstances," and an "independent probe by the state Department of Public Health ... is needed to determine whether the detainees are being treated properly" (San Diego Tribune, 5/19).

generic viagra online


News of the day
New Glaucoma Treatment To Be Piloted, Wales
New ways of diagnosing and treating patients with glaucoma will be piloted in two areas in Wales, Health Minister Edwina Hart announced today.
Cardiovascular

King Provides Additional Information On The REMOXY® NDA Resubmission Plan

King Pharmaceuticals, Inc. (NYSE: KG) announced additional information regarding the resubmission plan for the REMOXY® New Drug Application (NDA). The Company is not required by the Food and Drug Administration (FDA) to conduct clinical trials in order to provide additional safety or efficacy data in patients with moderate to severe chronic pain. However, as part of the resubmission plan, and in order to strengthen the NDA, King plans to conduct a likeability study and a pharmacokinetic trial in volunteers. The Company continues to anticipate the resubmission could occur mid-year 2010. About REMOXY® REMOXY, an investigational drug, is a unique, long-acting oxycodone formulation for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, Pain Therapeutics received a Complete Response Letter from the FDA. Subsequent to the receipt of the Complete Response Letter, King assumed full control of all activities related to the development of REMOXY®. About King Pharmaceuticals, Inc. King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products that complement the Company"s focus in specialty-driven markets, particularly neuroscience, hospital care. King"s wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacturing and marketing of pharmaceutical products for food producing animals. Forward Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). King Pharmaceuticals, Inc. disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the resubmission of the NDA for REMOXY® and the timing and content of any such resubmission; the need to generate any information or conduct any study or trial in connection with the resubmission and the timing of any such study or trial. Such statements are based on management"s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in preparation and resubmission of the NDA for REMOXY® and whether or when the NDA for REMOXY®,; the outcomes of any study or trial conducted in connection with the resubmission; and whether or when the NDA is approved by the FDA. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of King"s Annual Report on Form 10-K for the year ended December 31, 2008 and it"s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, each of which is on file with the U.S. Securities and Exchange Commission. King Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009